Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?

Diabetologia

Volumn 60, Issue 5, 2017, Pages 800-807

  Florez, Jose C ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Genome wide association studies; Metformin; Pharmacogenetics; Review; Single nucleotide polymorphisms; Sulfonylureas; TCF7L2; Type 2 diabetes

Indexed keywords

ABCC8 PROTEIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; ORGANIC CATION TRANSPORTER 1; PROTEIN; SULFONYLUREA; TRANSCRIPTION FACTOR 7 LIKE 2; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

DNA POLYMORPHISM; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PHARMACOGENETIC TESTING; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; DIABETES MELLITUS, TYPE 2; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM;

DIABETES MELLITUS, TYPE 2; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECISION MEDICINE;

EID: 85014781627     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4227-1     Document Type: Review

References (57)

1. Florez JC (2013) Pharmacogenetic perturbations in humans as a tool to generate mechanistic insight. Diabetes 62:3019–3021
2. Maruthur NM, Gribble MO, Bennett WL et al (2014) The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care 37:876–886
3. Huang C, Florez JC (2011) Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Med 3:76
4. Zhou K, Pedersen HK, Dawed AY, Pearson ER (2016) Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. Nat Rev Endocrinol 12:337–346
5. Gloyn AL, Pearson ER, Antcliff JF et al (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838–1849
6. Babenko AP, Polak M, Cave H et al (2006) Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 355:456–466
7. Greeley SA, Naylor RN, Philipson LH, Bell GI (2011) Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep 11:519–532
8. Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477
9. Gloyn AL, Weedon MN, Owen KR et al (2003) Large-scale association studies of variants in genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52:568–572
10. Florez JC, Burtt N, de Bakker PI et al (2004) Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 53:1360–1368
11. + channel. Diabetes 58:2419–2424
12. Feng Y, Mao G, Ren X et al (2008) Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 31:1939–1944
13. Javorsky M, Klimcakova L, Schroner Z et al (2012) KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med 23:245–249
14. Ragia G, Tavridou A, Petridis I, Manolopoulos VG (2012) Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diabetes Res Clin Pract 98:119–124
15. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:429–442
16. Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193–203
17. Rodbard HW, Jellinger PS, Davidson JA et al (2009) Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15:540–559
18. Kirpichnikov D, McFarlane SI, Sowers JR (2002) Metformin: an update. Ann Intern Med 137:25–33
19. Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443
20. Zeitler P, Hirst K, Pyle L et al (2012) A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 366:2247–2256
21. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334:574–579
22. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607–614
23. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223–228
24. Fryer LGD, Parbu-Patel A, Carling D (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277:25226–25232
25. Zhou G, Myers R, Li Y et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174
26. Foretz M, Hebrard S, Leclerc J et al (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120:2355–2369
27. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ (2013) Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494:256–260
28. Todd JN, Florez JC (2014) An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics 15:529–539
29. Shu Y, Sheardown SA, Brown C et al (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422–1431
30. Zhou K, Donnelly LA, Kimber CH et al (2009) Reduced function SLC22A1 polymorphisms encoding Organic Cation Transporter 1 (OCT1) and glycaemic response to metformin: A Go-DARTS study. Diabetes 58:1434–1439
31. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER (2015) Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: A GoDARTS Study. Diabetes 64:1786–1793
32. Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC (2009) Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study. Diabetes 58:745–749
33. Jablonski KA, McAteer JB, de Bakker PI et al (2010) Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the Diabetes Prevention Program. Diabetes 59:2672–2681
34. Tkac I, Klimcakova L, Javorsky M et al (2013) Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab 15:189–191
35. Dujic T, Zhou K, Yee SW et al (2016) Variants in pharmacokinetic transporters and glycaemic response to metformin: a MetGen meta-analysis. Clin Pharmacol Ther. doi:10.1002/cpt.567
36. Zhou K, Bellenguez C, Spencer CC et al (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43:117–120
37. van Leeuwen N, Nijpels G, Becker ML et al (2012) A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 55:1971–1977
38. Florez JC, Jablonski KA, Taylor A et al (2012) The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care 35:1864–1867
39. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC (2014) Metformin pharmacogenomics: current status and future directions. Diabetes 63:2590–2599
40. Zhou K, Yee SW, Seiser EL et al (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48:1055–1059
41. McCulloch LJ, van de Bunt M, Braun M, Frayn KN, Clark A, Gloyn AL (2011) GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus. Mol Genet Metab 104:648–653
42. Florez JC (2016) Leveraging genetics to advance type 2 diabetes prevention. PLoS Med 13:e1002102
43. Grant SFA, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323
44. Gaulton KJ, Nammo T, Pasquali L et al (2010) A map of open chromatin in human pancreatic islets. Nat Genet 42:255–259
45. Xia Q, Chesi A, Manduchi E et al (2016) The type 2 diabetes presumed causal variant within TCF7L2 resides in an element that controls the expression of ACSL5. Diabetologia 59:2360–2368
46. Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250
47. Liu Z, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723–8735
48. Loos RJF, Franks PW, Francis RW et al (2007) TCF7L2 polymorphisms modulate proinsulin levels and β-cell function in a British Europid population. Diabetes 56:1943–1947
49. Kirchhoff K, Machicao F, Haupt A et al (2008) Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 51:597–601
50. da Silva Xavier G, Loder MK, McDonald A et al (2009) TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 58:894–905
51. Pilgaard K, Jensen CB, Schou JH et al (2009) The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 52:1298–1307
52. Villareal DT, Robertson H, Bell GI et al (2010) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 59:479–485
53. Bailey KA, Savic D, Zielinski M et al (2015) Evidence of non-pancreatic beta cell-dependent roles of Tcf7l2 in the regulation of glucose metabolism in mice. Hum Mol Genet 24:1646–1654
54. Pearson ER, Donnelly LA, Kimber C et al (2007) Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes 56:2178–2182
55. Schroner Z, Javorsky M, Tkacova R et al (2011) Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab 13:89–91
56. Walford GA, Colomo N, Todd JN et al (2015) The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes. PLoS ONE 10:e0121553
57. Rena G, Pearson ER, Sakamoto K (2013) Molecular mechanism of action of metformin: old or new insights? Diabetologia 56:1898–1906